Answers are grounded in this paper and cite their sources.
Background: In low- and middle-income countries, where most healthcare expenses are paid out-of-pocket, the high cost of essential medications like antibiotics can compromise treatment adherence and increase the financial burden on patients. Antibiotics with identical active ingredients are marketed under various brand names with significant price disparities. This study aims to evaluate the price variation and cost ratio among commonly prescribed antibiotics used for surgical prophylaxis in a tertiary care hospital. Methodology: A prospective, cross-sectional observational study was conducted from September 2024 to March 2025 in the general surgery department of a tertiary care teaching hospital. Commonly prescribed antibiotics for surgical prophylaxis were identified from inpatient records. The maximum and minimum prices of different brands for each antibiotic were collected from standard drug pricing sources, including the Current Index of Medical Specialties, Indian Drug Review, and verified online pharmacies. Percentage price variation and cost ratio were calculated for each antibiotic. Results: Substantial price variations were observed among different brands of the same antibiotic. Amikacin and amoxicillin–potassium clavulanate exhibited the highest percentage price variations (354.9% and 321.4%, respectively), while vancomycin and metronidazole showed the least variation (14.3% and 19.2%). These findings highlight the potential for cost savings through judicious brand selection. Conclusion: The study emphasizes the importance of cost-conscious prescribing in antibiotic prophylaxis. Promoting the use of lower-cost but therapeutically equivalent brands can enhance affordability, improve adherence, and reduce the overall financial burden on patients.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: